Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
Neurocrine Biosciences, Inc. on July 1 announced the U.S. Food and Drug Administration (FDA) has accepted its two New Drug Applications (NDA) with Priority Review designations for crinecerfont in the treatment of children, adolescents, and adults with classic congenital adrenal hyperplasia (CAH). If approved, crinecerfont would be the first new treatment option for CAH in...
Discussing endocrine science with the 2024 Early Investigator Award Winners Every year the Endocrine Society recognizes endocrinologists who are in the early stages of their research careers with the Early Investigator Awards. Endocrine News spoke to the five award recipients from around the world to find out more about their award-winning research, the award’s potential...
Many of us are now fully back at our day job having returned from last month’s ENDO in Boston. The meeting was a fabulous success. There was such a buzz around the conference center, where friends and colleagues, old and new, met to discuss the very best in science and clinical practice. Congratulations and a...
When his grandmother succumbed to a heart attack when he was only eight years old, Joshua J. Joseph, MD, MPH, was determined to end as much suffering as he could. The recipient of the Endocrine Society’s 2024 Richard E. Weitzman Outstanding Early Career Investigator Award, he details his ongoing endeavors to make sure Black Americans...
